Corporate GovernanceMay 28, 2026, 04:20 PM
Pacira BioSciences: Glass Lewis Recommends "FOR" Director Nominees
AI Summary
Pacira BioSciences announced that Glass Lewis & Co., LLC, a leading independent proxy advisory firm, has recommended that Pacira stockholders vote "FOR" all three of Pacira's director nominees and "AGAINST" all three of DOMA Perpetual Capital Management LLC's nominees. Glass Lewis cited Pacira's actionable 5x30 plan designed to deliver substantial stockholder value by 2030, supported by a 37% one-year total stockholder return in 2025 and a 23.8% cumulative return since the strategy's launch. The firm also noted the Company's new pipeline products and efforts to protect intellectual property, while questioning DOMA's nominees' skills and alignment.
Key Highlights
- Glass Lewis recommends voting "FOR" Pacira's three director nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans.
- Glass Lewis recommends voting "AGAINST" all three of DOMA Perpetual Capital Management LLC's nominees.
- Pacira achieved a one-year total stockholder return of 37% for calendar year 2025.
- Cumulative total stockholder return was 23.8% since the 5x30 strategy launch on January 10, 2025.
- Pacira has filed 21 Orange Book-listed patents across two families.
- The Annual Meeting of Stockholders is scheduled for June 9, 2026.
Price Impact
More from PCRX